Panmure Gordon Reiterates “Buy” Rating for Vernalis plc (VER)

Vernalis plc (LON:VER)‘s stock had its “buy” rating reiterated by research analysts at Panmure Gordon in a research report issued to clients and investors on Thursday. They presently have a GBX 76 ($0.99) price objective on the stock. Panmure Gordon’s price objective points to a potential upside of 83.65% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Shore Capital reaffirmed a “house stock” rating on shares of Vernalis plc in a report on Tuesday, July 19th. Canaccord Genuity raised their price target on Vernalis plc from GBX 84 ($1.10) to GBX 88 ($1.15) and gave the company a “buy” rating in a report on Thursday. N+1 Singer reaffirmed a “hold” rating and issued a GBX 46 ($0.60) price target on shares of Vernalis plc in a report on Thursday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 99 ($1.29) price target on shares of Vernalis plc in a report on Thursday. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of GBX 73 ($0.95).

Vernalis plc (LON:VER) opened at 41.3832 on Thursday. Vernalis plc has a 1-year low of GBX 31.00 and a 1-year high of GBX 79.00. The firm’s market capitalization is GBX 184.21 million. The company has a 50 day moving average price of GBX 43.63 and a 200-day moving average price of GBX 45.70.

In other news, insider Carol Ferguson acquired 28,000 shares of Vernalis plc stock in a transaction dated Friday, September 30th. The shares were purchased at an average cost of GBX 41 ($0.54) per share, for a total transaction of £11,480 ($14,984.99).

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.